The MEDRAD® EOL Reference

ANCHOR RESOURCE · CT · MR · ANGIOGRAPHY

Four MEDRAD® injector platforms. Two deadlines. One supply path that doesn't end when Bayer's service does. This reference maps Bayer's published end-of-life dates across radiology — and how a facility keeps imaging without an unplanned capital upgrade, on its own timeline.

4	2	3	1
EOL PLATFORMS	DEADLINES · 2025 / 2028	MODALITIES	SUPPLY PATH

Written for Radiology Administrators, Value Analysis Committees, and Supply Chain leaders managing the MEDRAD® installed base through the Bayer end-of-life wave.

About this document. Bayer end-of-life notices are summarized and attributed for informational purposes; the full letters are available through Bayer's customer portal and are linked from the SEVA EOL Resources page. SEVA Devices™ is an independent supplier of medical disposables and is not affiliated with, authorized by, endorsed by, or sponsored by Bayer. MEDRAD® , Mark V ProVis, Spectris, Spectris Solaris, and Stellant are trademarks of Bayer.

EXECUTIVE SUMMARY

Four platforms. Two deadlines. One decision.

Bayer has issued end-of-life notifications for four MEDRAD® power-injector platforms spanning CT, MR, and angiography. Two — the Mark V ProVis angiographic injector and the original Spectris Solaris MR — reached end-of-service on **December 31, 2025**. Two more — Stellant Classic CT and the Spectris Solaris EP MR (including EP Mobile) — follow on **December 31, 2028**.

For a radiology department, none of these is an isolated product retirement: as each date passes, Bayer withdraws service, parts, technical support, and its own consumable supply for that platform. The injectors themselves are not recalled and keep working.

> THE DECISION EACH FACILITY FACES
>
> Replace a working injector on Bayer's timeline — or keep it running on an independent, validated disposable supply and make the capital decision on your own schedule. SEVA Devices™ supplies OEM-grade disposables for all four platforms, after the OEM exits.

The pages that follow lay out the published EOL dates by stage, all four platforms at a glance, each end-of-life notice with attribution, and SEVA's continuing-supply position for every platform — with the evaluation path a VAC can act on.

THE EOL TIMELINE

Four EOL stages — and where SEVA fits.

Bayer's published EOL notices move the affected platforms through four stages — coverage, service, replacement, and end of support. Two are already through it: the Mark V ProVis and the original Spectris Solaris MR reached end-of-service on 12/31/2025 and sit at End of Life today. The four stages below track the platforms still in transition — the Stellant Classic and Spectris Solaris EP, ahead of the 2028 cutoff — so you can plan against those dates instead of reacting under deadline.

01 **Coverage Renewal** CLOSED 12/31/2025

The last window to purchase full-service support coverage for the affected platforms. It has already closed for all four EOL platforms.

02 **Limited Service** 2026 ONWARD

Service availability narrows and replacement parts become harder to source as the platform nears end of support. The current window for Stellant Classic and Spectris Solaris EP facilities.

03 **Replacement Platforms** BEFORE 12/31/2028

Bayer's recommended successors — Stellant FLEX and Centargo (CT), MRXperion (MR), and Mark 7 Arterion (Angio) — use new proprietary disposables and require fresh capital per injector head.

04 **End of Life** AFTER 12/31/2028

No Bayer service, parts, consumables, or support. Without an independent disposables supplier, the equipment becomes unsupported.

WHERE SEVA FITS

When the disposables stay available, a working injector stays clinically usable through every stage. A validated, independent disposable supply keeps the injector running through stages 2–4 — so the upgrade stays a **choice on your timeline**, not a deadline.

REFERENCE

The four platforms at a glance

Every affected MEDRAD® platform, its Bayer end-of-service date and recommended upgrade, and the matched SEVA SKU that keeps it supplied. One SEVA MR kit (HS-MMD115T) serves both the Spectris Solaris and the Solaris EP injector.

PLATFORM	MODALITY	BAYER EOL	BAYER'S UPGRADE	SEVA KIT	SEVA SUPPLY
Mark V ProVis	Angio	12/31/2025	Mark 7 Arterion	**HS-MA150**	**Continuing**
Spectris Solaris MR	MR	12/31/2025	MRXperion	**HS-MMD115T**	**Continuing**
Stellant Classic CT	CT	12/31/2028	Stellant FLEX + Certegra	**HS-DCD201 / HS-DC201**	**Continuing**
Spectris Solaris EP MR / EP Mobile	MR	12/31/2028	MRXperion	**HS-MMD115T**	**Continuing**

SEVA kit references per the SEVA Devices product catalog (September 2025). "Bayer's Upgrade" lists the OEM's recommended replacement, shown for orientation only.

READ THE TABLE THIS WAY

The "Bayer EOL" column is when Bayer's support ends. The "SEVA Supply" column is independent of it: across all four platforms, validated disposables continue. The EOL date sets the service clock — not the disposable clock.

PLATFORM DETAIL · 1 OF 3

CT

MEDRAD® Stellant Classic CT CT EOL 12/31/2028

Bayer's notice ends service, parts, technical support, and its consumable supply for the Stellant Classic installed base after the cutoff; the coverage-renewal window closed 12/31/2025. Bayer's recommended upgrade is the Stellant FLEX with the Certegra® Workstation.

SEVA's position. 200 mL CT syringe kits continue — SEVA HS-DCD201 (dual) and HS-DC201 (single), validated for the Stellant injector system across both Classic and FLEX configurations.

Source: Bayer EOL Notification, October 2024, ref. PP-CTD-US-0219-1 (J. Carbone, Bayer Radiology).

PLATFORM DETAIL · 2 OF 3

MR — the Spectris Solaris family

MEDRAD® Spectris Solaris MR MR EOL 12/31/2025

Bayer's notice ends service, parts, support, and its consumable supply for the original Spectris Solaris MR after the cutoff. It explicitly does not apply to the Spectris Solaris EP MR. Bayer's recommended upgrade is the MEDRAD® MRXperion.

SEVA's position. MR syringe kits continue — SEVA HS-MMD115T (OEM SSQK65/115VS), the 65 mL + 115 mL kit for the Spectris Solaris.

Source: Bayer EOL Notification, June 2024, ref. PP-MRD-US-0050-1 (J. Carbone, Bayer Radiology).

MEDRAD® Spectris Solaris EP MR / EP Mobile MR EOL 12/31/2028

The EP MR and EP Mobile carry a separate, later Bayer end-of-service date than the original Solaris. Bayer's recommended upgrade is the MEDRAD® MRXperion.

SEVA's position. The same SEVA kit serves the EP injector — HS-MMD115T. The later 2028 date changes the service timeline, not the disposable: one SKU resupplies both the Solaris and the EP.

Source: Bayer EOL Notification, ref. PP-MRD-US-0052-1.

ONE KIT, BOTH INJECTORS, BOTH DATES

Because a single SEVA kit covers the Solaris and the EP, the family's two different deadlines collapse into one disposable decision. Whichever injector a facility runs, and whenever its service ends, the syringe supply is the same and continues.

PLATFORM DETAIL · 3 OF 3

Angiography

MEDRAD® Mark V ProVis ANGIO EOL 12/31/2025

Bayer's notice ends service, preventative maintenance, calibration, replacement parts, technical support, and its consumable supply for the U.S. installed base after the cutoff. The hardware is not recalled. Bayer's recommended upgrade is the MEDRAD® Mark 7 Arterion.

SEVA's position. Complete 150 mL angiographic injection kits continue — SEVA HS-MA150 (OEM 150-FT-Q), covering the Mark V, Mark V Plus, and Mark V ProVis injector systems.

Source: Bayer EOL Notification, June 2024, ref. PP-M-PRV-US-0044-1 (J. Carbone, Bayer Radiology).

EOL notices are paraphrased for informational purposes; the full Bayer letters are linked from the SEVA EOL Resources page. SEVA Devices is not affiliated with Bayer. Mark 7 Arterion, Stellant FLEX, and Certegra are Bayer product names.

THE WAY FORWARD

Independent disposables keep the choice yours.

The pressure to upgrade rests on one assumption — that when Bayer stops supplying, the facility has nowhere else to go. An independent, validated disposable supply removes that assumption, and with it the deadline pressure.

What SEVA supplies

- OEM-grade kits for CT, MR, and angiography, validated for fit and function on the platforms you run
- Sterile, EtO-validated, single-use, lot-traceable, packaged for the sterile back table
- One catalog across MEDRAD®, Bracco, Guerbet, Nemoto, and GE/Ulrich platforms
- Documented continuity-of-supply language and held lead times in every agreement

What SEVA does not sell

- No injectors — SEVA has no capital equipment to sell
- No service contracts and nothing to bundle
- No contrast media — your contrast and formulary choices stay entirely your own
- No OEM product roadmap — your purchasing decisions stay your own

INDEPENDENT OF CAPITAL — AND OF CONTRAST

The only thing that changes is who supplies the disposables. Keep your injector, keep the contrast agent and the partner your radiology team prefers, and decide on any future capital purchase on clinical and financial merit — on your own timeline.

THE PATH FORWARD

From this reference to a contracted supply

1 **Request the cross-reference and samples**

Send your platform and disposable usage; SEVA returns the matched SKUs with confirmed OEM references and evaluation samples.

2 Clinical & VAC evaluation

Your team reviews the evaluation kit and validation summary. SEVA supports the VAC packet with documentation, not a push toward new capital.

3 Contract direct

Hospital, IDN, and GPO contracting handled in-house, with continuity-of-supply language and agreed lead times written in — no bundling with contrast, service, or capital.

4 Order and resupply

SEVA SKUs go on your item master. Reorder against the platform on standard terms — the injectors keep running, the supply line stays open.

Start your platform transition

Cross-reference, evaluation kits, and contracting — one point of contact.

sales@sevadevices.com

sevadevices.com · +1 878-808-9500